My Way is a progestin-only emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. To obtain optimal efficacy, the tablet should be taken as soon as possible within 72 hours of intercourse. My Way is available only by prescription for women younger than age 17 years, and available over the counter for women 17 years and older. M...
Take My Way orally as soon as possible within 72 hours after unprotected intercourse or a known or suspected contraceptive failure. Efficacy is better if the tablet is taken as soon as possible after unprotected intercourse. My Way can be used at any time during the menstrual cycle. If vomiting occurs within two hours of taking the tablet, consideration should be given to repeating the dose.
The My Way (Levonorgestrel) tablet , 1.5 mg is available in a PVC/aluminum foil blister package. The tablet is a white to off-white, round, flat tablet debossed with “NL 620” on one side and plain on the other side containing 1.5 mg of levonorgestrel. NDC 43386-620-30 (1 tablet unit of use package) Store My Way at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
www.fda.gov/medwatch
www.mywaypill.comMy Way is a progestin-only emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. To obtain optimal efficacy, the tablet should be taken as soon as possible within 72 hours of intercourse.
My Way is available only by prescription for women younger than age 17 years, and available over the counter for women 17 years and older. My Way is not indicated for routine use as a contraceptive.
Take My Way orally as soon as possible within 72 hours after unprotected intercourse or a known or suspected contraceptive failure. Efficacy is better if the tablet is taken as soon as possible after unprotected intercourse. My Way can be used at any time during the menstrual cycle.
If vomiting occurs within two hours of taking the tablet, consideration should be given to repeating the dose.
The My Way tablet is supplied as a white to off-white, round, flat tablets containing 1.5 mg of levonorgestrel and debossed with “NL 620” on one side and plain on the other side.
My Way is contraindicated for use in the case of known or suspected pregnancy.
Ectopic pregnancies account for approximately 2% of all reported pregnancies. Up to 10% of pregnancies reported in clinical studies of routine use of progestin-only contraceptives are ectopic.
A history of ectopic pregnancy is not a contraindication to use of this emergency contraceptive method. Healthcare providers, however, should consider the possibility of an ectopic pregnancy in women who become pregnant or complain of lower abdominal pain after taking My Way. A follow-up physical or pelvic examination is recommended if there is any doubt concerning the general health or pregnancy status of any woman after taking My Way.
My Way is not effective in terminating an existing pregnancy.
Some women may experience spotting a few days after taking My Way. Menstrual bleeding patterns are often irregular among women using progestin-only oral contraceptives and women using levonorgestrel for postcoital and emergency contraception.
If there is a delay in the onset of expected menses beyond 1 week, consider the possibility of pregnancy.
My Way does not protect against HIV infection (AIDS) or other sexually transmitted infections (STIs).
A physical examination is not required prior to prescribing My Way. A follow-up physical or pelvic examination is recommended if there is any doubt concerning the general health or pregnancy status of any woman after taking My Way.
A rapid return of fertility is likely following treatment with My Way for emergency contraception; therefore, routine contraception should be continued or initiated as soon as possible following use of My Way to ensure ongoing prevention of pregnancy.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
My Way was studied in a randomized, double-blinded multicenter clinical trial. In this study, all women who had received at least one dose of study medication were included in the safety analysis: 1,379 women in the My Way group, and 1,377 women in the Plan B group (2 doses of 0.75 mg levonorgestrel taken 12 hours apart). The mean age of women given My Way was 27 years. The racial demographic of those enrolled was 54% Chinese, 12% Other Asian or Black, and 34% were Caucasian in each treatment group. 1.6% of women in the My Way group and 1.4% in Plan B group were lost to follow-up.
The most common adverse events (>10%) in the clinical trial for women receiving My Way included heavier menstrual bleeding (30.9%), nausea (13.7%), lower abdominal pain (13.3%), fatigue (13.3%), and headache (10.3%). Table 1 lists those adverse events that were reported in > 4% of My Way users.
| Most Common Adverse Events (MedDRA) | |
| Heavier menstrual bleeding | 30.9 |
| Nausea | 13.7 |
| Lower abdominal pain | 13.3 |
| Fatigue | 13.3 |
| Headache | 10.3 |
| Dizziness | 9.6 |
| Breast tenderness | 8.2 |
| Delay of menses (> 7 days) | 4.5 |
The following adverse reactions have been identified during post-approval use of Plan B (2 doses of 0.75 mg levonorgestrel taken 12 hours apart). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Gastrointestinal Disorders
Abdominal Pain, Nausea, Vomiting
General Disorders and Administration Site Conditions
Fatigue
Nervous System Disorders
Dizziness, Headache
Reproductive System and Breast Disorders
Dysmenorrhea, Irregular Menstruation, Oligomenorrhea, Pelvic Pain
Drugs or herbal products that induce certain enzymes, such as CYP3A4, may decrease the effectiveness of progestin-only pills. (7)
Drugs or herbal products that induce enzymes, including CYP3A4, that metabolize progestins may decrease the plasma concentrations of progestins, and may decrease the effectiveness of progestin-only pills. Some drugs or herbal products that may decrease the effectiveness of progestin-only pills include:
Significant changes (increase or decrease) in the plasma levels of the progestin have been noted in some cases of co-administration with HIV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors.
Consult the labeling of all concurrently used drugs to obtain further information about interactions with progestin-only pills or the potential for enzyme alterations.
Many studies have found no harmful effects on fetal development associated with long-term use of contraceptive doses of oral progestins. The few studies of infant growth and development that have been conducted with progestin-only pills have not demonstrated significant adverse effects.
In general, no adverse effects of progestin-only pills have been found on breastfeeding performance or on the health, growth, or development of the infant. However, isolated post-marketing cases of decreased milk production have been reported. Small amounts of progestins pass into the breast milk of nursing mothers taking progestin-only pills for long-term contraception, resulting in detectable steroid levels in infant plasma.
Safety and efficacy of progestin-only pills for long-term contraception have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents less than 17 years and for users 17 years and older. Use of My Way emergency contraception before menarche is not indicated.
This product is not intended for use in postmenopausal women.
No formal studies have evaluated the effect of race. However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both Plan B and the Yuzpe regimen (another form of emergency contraception). There was a non-statistically significant increased rate of pregnancy among Chinese women in the My Way trial. The reason for this apparent increase in the pregnancy rate with emergency contraceptives in Chinese women is unknown.
No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablet.
No formal studies were conducted to evaluate the effect of renal disease on the disposition of My Way.
Levonorgestrel is not a controlled substance. There is no information about dependence associated with the use of My Way.
There are no data on overdosage of My Way, although the common adverse event of nausea and associated vomiting may be anticipated.
The My Way Tablet contains 1.5 mg of a single active steroid ingredient, levonorgestrel [18,19-Dinorpregn-4-en-20-yn-3-one-13-ethyl-17-hydroxy-, (17α)-(-)-], a totally synthetic progestogen. The inactive ingredients are colloidal silicon dioxide, pregelatinized starch, lactose monohydrate, magnesium stearate, and talc.
Levonorgestrel has a molecular weight of 312.45, and the following structural and molecular formulas:
Emergency contraceptive pills are not effective if a woman is already pregnant. My Way is believed to act as an emergency contraceptive principally by preventing ovulation or fertilization (by altering tubal transport of sperm and/or ova). In addition, it may inhibit implantation (by altering the endometrium). It is not effective once the process of implantation has begun.
Absorption
Following a single dose administration of My Way in 30 women under fasting conditions, maximum plasma concentrations of levonorgestrel of 19.1 ng/mL were reached at 1.7 hours. See Table 2.
of My Way (levonorgestrel) tablet 1.5 mg to 30 Healthy Female Volunteers under Fasting Conditions[/TC]
| Mean (± SD) | |||||
| Cmax(ng/mL) | AUCt(ng·hr/mL)* | AUCinf(ng·hr/mL)* | Tmax(hr)** | t1/2 (hr) | |
| Levonorgestrel | 19.1 ( 9.7) | 294.8(208.8) | 307.5(218.5) | 1.7(1.0-4.0) | 27.5(5.6) |
Cmax = maximum concentration
AUCt = area under the drug concentration curve from time 0 to time of last determinable concentration
AUCinf = area under the drug concentration curve from time 0 to infinity
Tmax = time to maximum concentration
t1/2 = elimination half life
* N=29
** median (range)
Effect of Food: The effect of food on the rate and the extent of levonorgestrel absorption following single oral administration of My Way has not been evaluated.
Distribution
The apparent volume of distribution of levonorgestrel is reported to be approximately 1.8 L/kg. It is about 97.5 to 99% protein-bound, principally to sex hormone binding globulin (SHBG) and, to a lesser extent, serum albumin.
Metabolism
Following absorption, levonorgestrel is conjugated at the 17β-OH position to form sulfate conjugates and, to a lesser extent, glucuronide conjugates in plasma. Significant amounts of conjugated and unconjugated 3α, 5β-tetrahydrolevonorgestrel are also present in plasma, along with much smaller amounts of 3α, 5α-tetrahydrolevonorgestrel and 16β-hydroxylevonorgestrel. Levonorgestrel and its phase I metabolites are excreted primarily as glucuronide conjugates. Metabolic clearance rates may differ among individuals by several-fold, and this may account in part for the wide variation observed in levonorgestrel concentrations among users.
Excretion
About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates.
Specific Populations
Pediatric
This product is not intended for use in the premenarcheal population, and pharmacokinetic data are not available for this population.
Geriatric
This product is not intended for use in postmenopausal women, and pharmacokinetic data are not available for this population.
Race
No formal studies have evaluated the effect of race. However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both Plan B and the Yuzpe regimen (another form of emergency contraception). There was a non-statistically significant increased rate of pregnancy among Chinese women in the My Way trial. The reason for this apparent increase in the pregnancy rate with emergency contraceptives in Chinese women is unknown [see USE IN SPECIFIC POPULATIONS (8.6)].
Hepatic Impairment
No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of My Way.
Renal Impairment
No formal studies were conducted to evaluate the effect of renal disease on the disposition of My Way.
Drug-Drug Interactions
No formal drug-drug interaction studies were conducted with My Way [see DRUG INTERACTIONS (7)].
Carcinogenicity: There is no evidence of increased risk of cancer with short-term use of progestins. There was no increase in tumorgenicity following administration of levonorgestrel to rats for 2 years at approximately 5 µg/day, to dogs for 7 years at up to 0.125 mg/kg/day, or to rhesus monkeys for 10 years at up to 250 µg/kg/day. In another 7 year dog study, administration of levonorgestrel at 0.5 mg/kg/day did increase the number of mammary adenomas in treated dogs compared to controls. There were no malignancies.
Genotoxicity: Levonorgestrel was not found to be mutagenic or genotoxic in the Ames Assay, in vitro mammalian culture assays utilizing mouse lymphoma cells and Chinese hamster ovary cells, and in an in vivo micronucleus assay in mice.
Fertility: There are no irreversible effects on fertility following cessation of exposures to levonorgestrel or progestins in general.
A double-blind, randomized, multicenter, multinational study evaluated and compared the efficacy and safety of three different regimens for emergency contraception. Subjects were enrolled at 15 sites in 10 countries; the racial/ethnic characteristics of the study population overall were 54% Chinese, 34% Caucasian, and 12% Black or Asian (other than Chinese). 2,381 healthy women with a mean age of 27 years, who needed emergency contraception within 72 hours of unprotected intercourse were involved and randomly allocated into one of the two levonorgestrel groups. A single dose of 1.5 mg of levonorgestrel (My Way) was administered to women allocated into group 1. Two doses of 0.75 mg levonorgestrel 12 hours apart (Plan B) were administered to women in group 2. In the My Way group, 16 pregnancies occurred in 1,198 women and in the Plan B group, 20 pregnancies occurred in 1,183 women. The number of pregnancies expected in each group was calculated based on the timing of intercourse with regard to each woman’s menstrual cycle. Among women receiving My Way, 84% of expected pregnancies were prevented and among those women taking Plan B, 79% of expected pregnancies were prevented. The expected pregnancy rate of 8% (with no contraceptive use) was reduced to approximately 1% with My Way.
Emergency contraceptives are not as effective as routine contraception since their failure rate, while low based on a single use, would accumulate over time with repeated use [see INDICATIONS AND USAGE (1)].
In the clinical study, bleeding disturbances were the most common adverse event reported after taking the levonorgestrel-containing regimens. More than half of the women had menses within two days of the expected time; however, 31% of women experienced change in their bleeding pattern during the study period; 4.5% of women had menses more than 7 days after the expected time.
The My Way (Levonorgestrel) tablet , 1.5 mg is available in a PVC/aluminum foil blister package. The tablet is a white to off-white, round, flat tablet debossed with “NL 620” on one side and plain on the other side containing 1.5 mg of levonorgestrel.
NDC 43386-620-30 (1 tablet unit of use package)
Store My Way at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Mfg. by:
Novel laboratories, Inc.
Somerset, NJ
Distributed by:
Gavis Pharmaceuticals, LLC
Somerset, NJ
PI 62030002001
Medication Guide
My Way
Emergency Contraceptive
Because the unexpected happens
Important information about My Way,
Birth Control and Sexually Transmitted Diseases
For additional information intended for healthcare professionals, please see enclosed Product Information for My Way.
What is My Way?
My Way is emergency contraception that helps prevent pregnancy after birth control failure or unprotected sex. It is a backup method of preventing pregnancy and is not to be used routinely.
My Way can reduce your chance of pregnancy after unprotected sex (if your regular birth control was used incorrectly or fails, or if you have had sex without birth control). For example, if you were using a condom and it broke or slipped, if you did not use your regular birth control as you should have, or if you did not use any birth control, My Way may work for you.
What My Way is not.
My Way will not work if you are already pregnant and will not affect an existing pregnancy. My Way should not be used as regular birth control. It is important to have another reliable source of birth control that is right for you. My Way will not protect you from HIV infection (the virus that causes AIDS) and other sexually transmitted diseases.
When is the appropriate time to use My Way?
You can use My Way after you have had unprotected sex in the last 72 hours (3 days), and you do not want to become pregnant.
My Way can be used as a backup or emergency method to regular birth control if, for example,
When is it not appropriate to use My Way?
How does My Way work?
My Way is one pill with levonorgestrel, a hormone that has been used in many birth control pills for over 35 years. My Way contains a higher dose of levonorgestrel than birth control pills, but works in a similar way to prevent pregnancy. It works mainly by stopping the release of an egg from the ovary. It is possible that My Way may also work by preventing fertilization of an egg (the uniting of sperm with the egg) or by preventing attachment (implantation) to the uterus (womb).
How can I get the best results from My Way?
You have only a few days to try to prevent pregnancy after unprotected sex. The sooner you take My Way, the better it works. My Way should be taken as soon as possible within 72 hours (3 days) after unprotected sex.
How effective is My Way?
The sooner you take My Way, the better it will work. Take My Way as soon as possible after unprotected sex. If it is taken as soon as possible within 72 hours (3 days) after unprotected sex, it will significantly decrease the chance that you will get pregnant. Seven out of every 8 women who would have gotten pregnant will not become pregnant.
How will I know if My Way worked?
Most women will have their menstrual period at the expected time or within a week of the expected time. If your menstrual period is delayed beyond 1 week, you may be pregnant. You should get a pregnancy test and follow up with your healthcare professional.
What if I am already pregnant and use My Way?
There is no medical evidence that My Way would harm a developing baby. If you take My Way (accidentally) after you are already pregnant or it does not work and you become pregnant, it is not likely to cause any harm to you or your pregnancy. The pregnancy will continue. My Way will not work if you are already pregnant.
What should I do if my menstrual period is delayed beyond 1 week and I have severe lower stomach (abdominal) pain?
If you have severe lower stomach (abdominal) pain about 3 to 5 weeks after taking My Way, you may have a pregnancy outside the uterus, which is called a tubal pregnancy. A tubal pregnancy requires immediate medical treatment, so you should see a healthcare professional right away.
Can I use My Way for regular birth control?
No. My Way should not be used for regular birth control. It is an emergency or backup method to be used if your regular birth control fails or is used incorrectly or if you have sex without birth control. You should protect yourself against STDs and pregnancy every time you have sex. If you have unprotected sex again after taking My Way, it will not help protect you from getting pregnant.
How often can I use My Way?
My Way is meant for emergency protection only, and is not designed to be used frequently. If you find that you need to use emergency contraception often, talk to your healthcare professional and learn about methods of birth control and STD prevention that are right for you.
Will I experience any side effects from My Way?
When used as directed, My Way is safe for women. Some women will have mild, temporary side effects, such as menstrual changes, nausea, lower stomach (abdominal) pain, tiredness, headache, dizziness, breast pain and vomiting. These are similar to the side effects that some women have when taking regular birth control pills. Some women taking My Way will have menstrual changes such as spotting or bleeding before their next period. Some women may have a heavier or lighter next period, or a period that is early or late. If your period is more than a week late, you should get a pregnancy test.
What warnings should I know about when using My Way?
My Way does not protect against AIDS virus (HIV) or other sexually transmitted diseases (STDs).
Do not use:
When using this product, you may have:
Keep out of reach of children.
In case of overdose, get medical help or contact a Poison Control Center right away at 1-800-222-1222.
What are the directions for using My Way?
Women 17 years of age and older:
What should I do if I have questions about My Way?
If you have questions or need more information about this product, call 1-800-422-8689, visit our website at www.mywaypill.com, or ask a healthcare professional.
Other information
Tablet is enclosed in a blister seal. Do not use if the blister seal is broken.
Store at room temperature 20–25°C (68–77°F).
You may report side effects to FDA at 1-800-FDA-1088.
Active ingredient: Levonorgestrel 1.5 mg
Inactive ingredients: Colloidal silicon dioxide, pregelatinized starch, magnesium stearate, talc, and lactose monohydrate
Protect yourself in more ways than one!
If you are sexually active, but you are not ready for a pregnancy, it is important to use regular pregnancy protection. There are many types of birth control. Whichever type you choose, it is important to use your regular birth control method as directed. This ensures that you have effective protection against pregnancy every time you have sex.
But things do not always go as planned. For example, if you were using a condom and it broke or slipped, or if you did not use your regular birth control as you should have, or if you did not use any birth control, My Way may work for you. My Way is an emergency contraceptive that helps prevent pregnancy after unprotected sex or when your birth control fails or is not used correctly.
Remember, My Way is only for emergency pregnancy prevention. There are many other products that work for regular birth control that are available by prescription or over-the-counter.
There is also another form of protection to think about when you have sex: protection against sexually transmitted diseases (STDs). Some common STDs are HIV/AIDS, Chlamydia, genital herpes, gonorrhea, hepatitis, human papilloma virus (HPV), genital warts, syphilis, and trichomonas. Some of these STDs can be very serious and can lead to infertility (inability to have a baby), problems during pregnancy, chronic illness, and even death.
All sexually active women are at risk of catching STDs because they may not know that their partner has an STD (the partner himself may not know). If your partner uses a latex condom correctly each and every time you have sex with him, this will help reduce, but not eliminate, the chance that you will catch an STD.
No other birth control methods will effectively protect you from STDs. The female condom may give you some STD protection, but it is not as effective as a male latex condom.
For more information on STDs, call the Centers for Disease Control and Prevention (CDC) AIDS/STD Hotline. The CDC phone numbers are 1-800-342-AIDS (2437) for English, 1-800-344-7432 for Spanish, or 1-800-243-7889 for hearing impaired, TDD.
Be sure to protect yourself against pregnancy and STDs by using some form of birth control plus a latex condom. Of course, not having sex is the most effective way to prevent pregnancy and stay free of STDs
My Way is used to prevent pregnancy after unprotected sex.
My Way should not be used for regular birth control, if you are already pregnant (because it will not work), or if you are allergic to levonorgestrel or any of the ingredients in My Way.
The sooner you take My Way, the better it will work.
My Way does not protect against the AIDS virus (HIV) or other sexually transmitted diseases (STDs)
Common side effects associated with the use of My Way include menstrual changes, nausea, lower stomach (abdominal) pain, tiredness, headache, dizziness, breast pain and vomiting.
NDC 43386-620-30
Levonorgestrel Tablet, 1.5 mg
Emergency Contraceptive
| Class | Version | Type | Effective |
|---|---|---|---|
| LEVONORGESTREL Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20230718 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 43386-620-30 | 2019-11-27 | C162847 | 48780-1 | 9855d018-e7a1-cd31-e053-dbdaa90ab51a | These highlights do not include all the information needed to use My Way safely and effectively. See full prescribing information for My Way. My Way (Levonorgestrel) TABLET for ORAL use. Initial U.S. Approval: 1982 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 43386-620-30 | My Way | 1 in 1 CARTON | TABLET | 1 | 1 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 43386-620-30 | EA - Each | 43386-620 | 05cdec40-5516-4602-a984-dc42de10e043 | 1 | 2013-04-01 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| LEVONORGESTREL | ACTIVE INGREDIENT | 5W7SIA7YZW | 1 | |
| LEVONORGESTREL | ACTIVE MOIETY | 5W7SIA7YZW | 1 | |
| LACTOSE MONOHYDRATE | INACTIVE INGREDIENT | EWQ57Q8I5X | 1 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 1 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| STARCH, CORN | INACTIVE INGREDIENT | O8232NY3SJ | 1 | |
| TALC | INACTIVE INGREDIENT | 7SEV7J4R1U | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 43386-620 | 43386-620-30 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| LEVONORGESTREL | 5W7SIA7YZW | ACTIB |
| SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
| STARCH, CORN | O8232NY3SJ | IACT |
| LACTOSE MONOHYDRATE | EWQ57Q8I5X | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| TALC | 7SEV7J4R1U | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET, COATED / ORAL | 256 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | LOZENGE / TRANSMUCOSAL | 100 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET / SUBLINGUAL | 409 mg | ||
| TALC | TALC | 7SEV7J4R1U | CAPSULE, COATED / ORAL | 87 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / ORAL | 602 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 520 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SYSTEM / INTRAVITREAL | 0.02 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, COATED / ORAL | 1301 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CREAM / VAGINAL | 51 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 336 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SUSPENSION / ORAL | 200 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET, ORALLY DISINTEGRATING / ORAL | 100 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CAPSULE, DELAYED RELEASE / ORAL | 2087 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | POWDER / ORAL | 50 mg | ||
| TALC | TALC | 7SEV7J4R1U | POWDER, FOR SUSPENSION / ORAL | 735 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / ORAL | 300 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, EXTENDED RELEASE / ORAL | 117 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER, FOR SUSPENSION / ORAL | 120 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, EXTENDED RELEASE / ORAL | 173 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION / ORAL | 64 mg | ||
| TALC | TALC | 7SEV7J4R1U | GRANULE / ORAL | 322 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 214 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CAPSULE, EXTENDED RELEASE / ORAL | 5364 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUSPENSION, EXTENDED RELEASE / ORAL | 70 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / ORAL | 25 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER, FOR SUSPENSION / ORAL | 2553 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FOR SUSPENSION / ORAL | 131 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, EXTENDED RELEASE / ORAL | 2575 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET / RECTAL | 32.4 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 53 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / BUCCAL | 17.5 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED / ORAL | 166 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 21 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUPPOSITORY / RECTAL | 14 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / DENTAL | 19 %w/w | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | WAFER / ORAL | 66 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 150 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, DELAYED RELEASE / ORAL | 144 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | POWDER, FOR SUSPENSION / ORAL | 34 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVERNOUS | 174 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | GRANULE, FOR SOLUTION / ORAL | 1691.8 mg/120ml | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET, ORALLY DISINTEGRATING / ORAL | 366 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / VAGINAL | 8 %w/w | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | NA | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CAPSULE / ORAL | 3990 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | PELLET / ORAL | 34 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, SUGAR COATED / ORAL | NA | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 9.5 %w/v | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / BUCCAL | 3 mg | ||
| LACTOSE MONOHYDRATE | LACTOSE MONOHYDRATE | EWQ57Q8I5X | CAPSULE, COATED / ORAL | 300 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | LOZENGE / ORAL | 120 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | DROPS / ORAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED / ORAL | 3 mg | ||
| STARCH, CORN | STARCH, CORN | O8232NY3SJ | SUSPENSION/ DROPS / ORAL | 90 mg | ||
| TALC | TALC | 7SEV7J4R1U | LOZENGE / ORAL | 50 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| TALC | TALC | 7SEV7J4R1U | OINTMENT / TOPICAL | 74.6 %w/w |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A202508-001 | LEVONORGESTREL | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A202508-001 | LEVONORGESTREL | 1.5MG | TABLET / ORAL | 2013-02-22 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 07b96626-aa19-4ce3-8ef5-c2cbebdb05f6 | c749c15a-2c92-4db9-a6b9-fdf18da5b7da | 2013-02-27 | Warnings, Adverse reactions | 07b96626-aa19-4ce3-8ef5-c2cbebdb05f6 c749c15a-2c92-4db9-a6b9-fdf18da5b7da |
Adverse event summaries are temporarily unavailable. Other product information remains available.